Enliven Therapeutics, Inc. (NASDAQ:ELVN) Given Consensus Rating of "Buy" by Analysts

Enliven Therapeutics, Inc. (NASDAQ:ELVN - Get Free Report) has earned an average recommendation of "Buy" from the five analysts that are presently covering the stock, MarketBeat Ratings reports. Five analysts have rated the stock with a buy rating. The average twelve-month price objective among analysts that have updated their coverage on the stock in the last year is $41.20.

ELVN has been the subject of several research analyst reports. The Goldman Sachs Group began coverage on Enliven Therapeutics in a report on Monday, June 16th. They issued a "buy" rating and a $37.00 price objective for the company. HC Wainwright boosted their price target on Enliven Therapeutics from $40.00 to $48.00 and gave the company a "buy" rating in a research note on Wednesday, July 2nd. Jones Trading lowered their price objective on shares of Enliven Therapeutics from $36.00 to $27.00 and set a "buy" rating on the stock in a research note on Friday, May 16th. Finally, Robert W. Baird boosted their target price on shares of Enliven Therapeutics from $40.00 to $52.00 and gave the company an "outperform" rating in a research report on Monday, June 16th.

Insiders Place Their Bets

In related news, insider Joseph P. Lyssikatos sold 12,500 shares of the firm's stock in a transaction on Friday, June 20th. The shares were sold at an average price of $21.40, for a total value of $267,500.00. Following the completion of the transaction, the insider directly owned 965,188 shares of the company's stock, valued at approximately $20,655,023.20. This trade represents a 1.28% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, CEO Samuel Kintz sold 12,500 shares of Enliven Therapeutics stock in a transaction on Tuesday, June 17th. The stock was sold at an average price of $22.18, for a total transaction of $277,250.00. Following the completion of the transaction, the chief executive officer directly owned 952,892 shares of the company's stock, valued at $21,135,144.56. The trade was a 1.29% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 100,111 shares of company stock worth $1,951,216 over the last quarter. Company insiders own 25.90% of the company's stock.

Institutional Investors Weigh In On Enliven Therapeutics

Several institutional investors have recently made changes to their positions in ELVN. Tower Research Capital LLC TRC lifted its stake in Enliven Therapeutics by 230.2% in the fourth quarter. Tower Research Capital LLC TRC now owns 1,598 shares of the company's stock worth $36,000 after purchasing an additional 1,114 shares during the last quarter. GAMMA Investing LLC lifted its stake in shares of Enliven Therapeutics by 3,058.1% during the 1st quarter. GAMMA Investing LLC now owns 2,716 shares of the company's stock worth $53,000 after acquiring an additional 2,630 shares during the last quarter. Quantbot Technologies LP bought a new stake in shares of Enliven Therapeutics during the 1st quarter worth approximately $60,000. KLP Kapitalforvaltning AS purchased a new position in Enliven Therapeutics during the 4th quarter valued at $97,000. Finally, BNP Paribas Financial Markets bought a new position in Enliven Therapeutics in the 4th quarter valued at $112,000. Institutional investors own 95.08% of the company's stock.

Enliven Therapeutics Stock Down 1.4%

Shares of ELVN stock traded down $0.33 during mid-day trading on Friday, hitting $22.45. The company's stock had a trading volume of 343,523 shares, compared to its average volume of 703,677. Enliven Therapeutics has a 52-week low of $13.30 and a 52-week high of $30.03. The business has a 50-day moving average price of $19.77 and a 200 day moving average price of $20.30.

Enliven Therapeutics (NASDAQ:ELVN - Get Free Report) last issued its quarterly earnings data on Wednesday, May 14th. The company reported ($0.57) earnings per share for the quarter, missing analysts' consensus estimates of ($0.51) by ($0.06). Equities analysts forecast that Enliven Therapeutics will post -1.95 earnings per share for the current fiscal year.

Enliven Therapeutics Company Profile

Enliven Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. The company's lead product candidates comprise ELVN-001, which is being evaluated in a Phase 1 clinical trial in adults with chronic myeloid leukemia; and ELVN-002, a Phase 1 clinical trial in adults with solid tumors with HER2 alterations.